Delafloxacin Intravenous and Kisqali (600 MG Dose)
Determining the interaction of Delafloxacin Intravenous and Kisqali (600 MG Dose) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ribociclib may increase the blood levels and effects of delafloxacin. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of breast cancer resistance protein (BCRP), organic cation transporter-2 (OCT-2), multidrug and toxin extrusion 1 (MATE1), and/or bile salt efflux pump (BSEP) transporters. The proposed mechanism, based on in vitro data, is decreased clearance due to ribociclib-mediated inhibition of these transport proteins at clinically relevant concentrations.
MANAGEMENT: Caution is advised if ribociclib is used concomitantly with drugs that are substrates of BCRP, OCT-2, MATE1, and/or BSEP transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever ribociclib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: delafloxacin
Brand name: Baxdela
Synonyms: Delafloxacin (oral/injection), Delafloxacin
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Delafloxacin Intravenous-Kisqali Femara Co-Pack
- Delafloxacin Intravenous-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Delafloxacin Intravenous-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Delafloxacin Intravenous-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose
- Delafloxacin Intravenous-Kitabis Pak
- Delafloxacin Intravenous-Kitabis Pak inhalation
- Kisqali (600 MG Dose)-Delafloxacin Meglumine
- Kisqali (600 MG Dose)-Delafloxacin oral/injection
- Kisqali (600 MG Dose)-Delafloxacin Tablets
- Kisqali (600 MG Dose)-Delatestryl
- Kisqali (600 MG Dose)-Delavirdine
- Kisqali (600 MG Dose)-Delavirdine Mesylate